CorMedix Inc. (CRMD)

CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.

- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant -

CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.

CorMedix is commercializing DefenCath, the only FDA-approved antimicrobial catheter-lock solution, with strong clinical results and rapid adoption in dialysis clinics. Medicare's TDAPA policy ensures full reimbursement for outpatient treatments, supporting near-term revenue as clinic penetration expands and inpatient rollout begins. Q2 2025 financials show $39.7M net revenue and $19.8M net income, with robust liquidity and growing contracts, including a major Large Dialysis Organization contributing significantly to sales.

CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.

CorMedix Inc. (NASDAQ:CRMD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Joseph Todisco - CEO & Director Conference Call Participants Ross Cohen Presentation Ross Cohen Okay. So thank you all for joining.

After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera's concurrently announced private placement financing.

The mean of analysts' price targets for CorMedix (CRMD) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.

- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -

BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September.

CorMedix has achieved GAAP profitability after years of losses, with the market yet to fully price in this turnaround. Shares trade at a moderate 17x forward P/E, but with a projected 8x forward P/E, I see further upside potential. DefenCath's FDA approval and successful commercialization underpin CorMedix's financial strength and independence from larger biotech partners.

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.